0921 GMT - Novo Nordisk expects a negative low-single-digit percentage impact on global sales growth in 2026 from its GLP-1 deal with the U.S. administration, and consensus might now expect only limited growth in 2026, Jefferies analysts write. Consensus might land at low-single-digit percentage sales growth in 2026, although the deal will enable higher Wegovy volumes through government channels longer term, Jefferies says. Eli Lilly and Novo Nordisk both received a voucher from the FDA that will speed up the review of their respective weight-loss pills. Earlier approval of Eli Lilly's orforglipron will likely be seen as a competitive headwind to Novo Nordisk, as approval of its Wegovy pill was already anticipated before year-end, Jefferies adds. Novo Nordisk shares fall 1.5%. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

November 07, 2025 04:21 ET (09:21 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.